Researchers reveal mechanism by which MAF protein increases metastasis risk in breast cancer patients

Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed each year. In cases where the tumour remains localised in the breast, survival rates are remarkably high, at around 90%. However, the spread of cancer cells beyond breast tissue and the formation of metastases in other organs dramatically worsens the prognosis and poses significant challenges. Previous research has already linked the MAF protein to an increased risk of developing metastasis, but the reasons for this connection remained unclear.

A team from IRB Barcelona ​​led by ICREA researcher Dr. Roger Gomis has revealed the mechanism by which the MAF protein increases the risk of metastasis in breast cancer patients. This finding is a crucial step in understanding the molecular basis of metastasis and has relevant clinical implications for treatment.

The research team has detailed in the journal Nature Cell Biology how the MAF protein interacts with the estrogen receptor, a key element in the development of breast cancer, modifying its structure. This interaction leads to DNA restructuring, which allows the activation of genes that favour metastasis, particularly in response to estrogen. These findings imply that patients with high levels of MAF protein have a greater risk of developing metastasis.

This study opens up the possibility of preventing metastasis by impeding the activation of pro-metastatic through the inhibition of the KDM1A molecule, which is responsible for DNA restructuring. This offers new perspectives in the treatment of breast cancer. The study was carried out in cultured cells and animal models of the disease, and it was validated in patient samples.

The research has been supported by the "la Caixa" Foundation through the 2018 Health Call. The project has also received funding by the Spanish Association Against Cancer, the FERO Foundation, the BBVA Foundation and the Spanish Ministry of Science and Innovation. The project has also been supported by Mrs. Carme Segura Capellades, who donates generously to cancer research at IRB Barcelona.

Crucial discovery for young and premenopausal patients

Previous studies by the same laboratory had already established a connection between increased MAF protein levels and resistance to "bisphosphonate" treatment used to prevent breast cancer metastasis to bone.

The detection of high levels of MAF can therefore predict the risk of metastasis, as well as distinguish between breast cancer patients who may benefit from bisphosphonate treatment from those for whom this treatment is inappropriate. This information is particularly crucial for young patients. Treatments aimed at the site of bone metastasis can, in some cases, divert metastasis to other organs, which has a negative impact on the overall survival of patients.

"This finding is a critical step in understanding how breast cancer spreads and opens up new therapeutic options for the 20% of patients who cannot benefit from bisphosphonate treatment," explains Dr. Gomis, head of the Growth Control and Cancer Metastasis laboratory at IRB Barcelona and also a group leader at the Cancer CIBER (CIBERONC).

The MAF Test: a diagnostic tool that is now available

The research carried out in Dr. Gomis' lab has led to the development of the MAF Test, a predictive tool available for breast cancer patients. This diagnostic test has been developed by Inbiomotion, a spin-off from IRB Barcelona and ICREA founded in 2011, and is available in Spain through PALEX Medical.

The MAF Test allows the identification of breast cancer patients with a greater risk of developing metastasis and facilitates informed decisions by oncologists about the most appropriate treatment for each case.

A drug currently in clinical trials could benefit these patients

An inhibitor of the element that researchers have identified as key in the metastatic drift of breast cancer, namely the KDM1A protein, has already been identified and is currently in clinical trials to validate its effectiveness and safety. This inhibitor and related trials are independent of the findings published today. However, if this potential drug is confirmed to be effective, it could offer significant benefits for patients with elevated MAF levels by helping to prevent the development of metastases.

The first authors of the study are Dr. Alicia Llorente, who started this work during her doctoral studies, Dr. Teresa Blasco, who also signs as responsible for the publication, together with Dr. Gomis and Irene Espuny. All three work in Dr. Gomis' laboratory. The research was carried out in collaboration with the laboratories headed by Dr. Luciano Di Croce, at the Center for Genomic Regulation, Dr. Alexandra Avgustinova at IRB Barcelona and the Institut de Recerca Sant Joan de Deu, and Dr. Ingunn Holen, at the University of Sheffield. The study also involved the groups led by Dr. Antoni Riera and Dr. Freddy Monteiro (both at IRB Barcelona), and Dr. Mariona Graupera, at the Josep Carreras Leukemia Research Institute.